Marex Group.png
Marex Group plc announces 2024 Interim Results
14 août 2024 07h00 HE | Marex Group plc
Marex Group plc announces 2024 Interim Results
SIDETRADE_LOGO_2019_MASTER_WEB.JPG
Sidetrade: +25% of Bookings, +19% of Revenue for H1 2024
16 juil. 2024 11h43 HE | Sidetrade
All-time performance for half-year bookings  €7.42 million in new Annual Contract Value (ACV): up 25% With €3.95 million in SaaS bookings (ARR): up 20%And €3.47 million in Services bookings: up...
Sidetrade : +25% en
Sidetrade : +25% en prises de commandes, +19% en CA S1 2024
16 juil. 2024 11h43 HE | Sidetrade
Un niveau de prises de commandes jamais atteint sur un semestre  Valeur annuelle de nouveaux contrats signés (ACV) à 7,42 M€ : +25% dont nouveaux abonnements SaaS (ARR) à 3,95 M€ : +20%dont...
Obseva Logo highresolution.jpg
ObsEva Files half Year 2023 Financial Statements
27 sept. 2023 01h00 HE | ObsEva SA
ObsEva Files half Year 2023 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – September 27, 2023 – ObsEva SA (SIX: OBSN), a...
INNATEvertnoir.png
Innate Pharma Reports First Half 2020 Financial Results and Business Update
08 sept. 2020 01h00 HE | INNATE PHARMA
Innate resumed enrollment of lacutamab TELLOMAK Phase 2 clinical trial for patients with Sézary syndrome and mycosis fungoidesMonalizumab Phase 3 study expected to initiate in the second half of 2020,...